New triple therapy offers hope for advanced lung cancer patients
NCT ID NCT07198217
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a sequence of platinum-based chemotherapy, followed by a special type of radiation (hypofractionated radiotherapy), and then the immunotherapy drug Tislelizumab. The goal is to see if this combination is safe and effective at controlling the cancer for at least one year. About 20 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOFRACTIONATED RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zibo Municipal Hospital
RECRUITINGZibo, Shandong, 250000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.